Use of picropodophyllin derivatives for treatment of igf-1r mediated disorders
CA 2451047 C · Owner: Axelson, Magnus · Inventors: Larsson, Olle; Axelson, Magnus
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides use of a compound of formula I: (see formula I), for prophylaxis or treatment of a condition that is leukemia malignant , melanoma, Ewing's sarcoma, breast cancer prostate cancer, neuroblastoma, glioma myeloma, lymphoma, a gastrointestinal tumor a gynecological cancer or lung , cancer cells of which express insulin-like growth factor-1 receptor and the , invention also provides use of a compound of formula I for treating a condition , which is psoriasis, arteriosclerosis restenosis after coronary angioplasty or acromegaly.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 19, 2002 and granted October 9, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 19, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 19, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.